A Comprehensive Insight on Pharmacological Properties of Cilnidipine: A
Fourth-generation Calcium Channel Blocker

Renu      Kadian; Arun      Nanda
doi:10.2174/1871525721666230224111518
Abstract

Preventing the development of cardiovascular problems is a key objective of antihypertensive drugs. Many of the non-pressure related coronary risk factors for hypertension are thought to be connected to an increase in sympathetic activity. The sympathetic systems have N-type calcium channels at the nerve terminals that control neurotransmitter release. Cilnidipine is a unique fourth-generation calcium channel blocker with blocking action on both L-/N- type calcium channels. Several L-type calcium channel blockers (Nilvadipine, amlodipine, azelnidipine, nifedipine, etc.) have been used to treat hypertensive patients. Cilnidipine is a novel drug that exerts a hypotensive effect through vasodilation action via blocking L-type calcium channels and potent antisympathetic activity via blocking N-type calcium channels. Inhibiting N-type calcium channels might be a new approach to treating cardiovascular disorders. Therefore, it is expected that cilnidipine may respond well to complicated hypertension. The present review aims to describe the management mechanism of hypertension, and other pharmacological and physicochemical properties of cilnidipine. Cilnidipine has various other beneficial effects such as lipid-lowering effect, reduced white coat effect, improves insulin sensitivity in essential hypertensive patients, ameliorates osteoporosis in ovariectomized hypertensive rats, reduced arterial stiffness, reduced the risk of pedal edema, antinociceptive effects, neuroprotective and renal protective effect, probably through inhibition of N-type calcium channels. Cilnidipine distinguishes itself from other calcium channel blockers due to its wide range of beneficial pharmacological effects. In conclusion, cilnidipine may be more advantageous than other dihydropyridines, such as nisoldipine, amlodipine, azelnidipine, and other antihypertensive drugs.
Keywords: Calcium channel blocker, cilnidipine, dihydropyridine, fourth generation calcium channel blocker, hypertension, metabolism, N-type calcium channel blocker.
« Previous Next »
Graphical Abstract

[1]
Kannel, W.B. Role of blood pressure in cardiovascular morbidity and mortality. Prog. Cardiovasc. Dis.,  1974, 17(1), 5-24.
 [http://dx.doi.org/10.1016/0033-0620(74)90034-6] [PMID:  4276031]

[2]
Staessen, J.A.; Wang, J.; Bianchi, G.; Birkenhäger, W.H. Essential hypertension. Lancet,  2003, 361(9369), 1629-1641.
 [http://dx.doi.org/10.1016/S0140-6736(03)13302-8] [PMID:  12747893]

[3]
Whitworth, J.A. 2003 World Health Organization (WHO)/international society of hypertension (ISH) statement on management of hypertension. J. Hypertens.,  2003, 21(11), 1983-1992.
 [http://dx.doi.org/10.1097/00004872-200311000-00002] [PMID:  14597836]

[4]
Giles, T.D.; Materson, B.J.; Cohn, J.N.; Kostis, J.B. Definition and classification of hypertension: An update. J. Clin. Hypertens. (Greenwich),  2009, 11(11), 611-614.
 [http://dx.doi.org/10.1111/j.1751-7176.2009.00179.x] [PMID:  19878368]

[5]
Head, G.A.; Mihailidou, A.S.; Duggan, K.A.; Beilin, L.J.; Berry, N.; Brown, M.A.; Bune, A.J.; Cowley, D.; Chalmers, J.P.; Howe, P.R.C.; Hodgson, J.; Ludbrook, J.; Mangoni, A.A.; McGrath, B.P.; Nelson, M.R.; Sharman, J.E.; Stowasser, M. Ambulatory blood pressure working group of the high blood pressure research council of Australia. Definition of ambulatory blood pressure targets for	diagnosis and treatment of hypertension in relation to clinic blood	pressure: Prospective cohort study. BMJ, 2010, 340(apr14 3),	c1104. 
 [http://dx.doi.org/ 10.1136/bmj.c1104] [PMID:   20392760]

[6]
Ferrannini, E.; Buzzigoli, G.; Bonadonna, R.; Giorico, M.A.; Oleggini, M.; Graziadei, L.; Pedrinelli, R.; Brandi, L.; Bevilacqua, S. Insulin resistance in essential hypertension. N. Engl. J. Med.,  1987, 317(6), 350-357.
 [http://dx.doi.org/10.1056/NEJM198708063170605] [PMID:  3299096]

[7]
Carretero, O.A.; Oparil, S. Essential hypertension. Circulation,  2000, 101(3), 329-335.
 [http://dx.doi.org/10.1161/01.CIR.101.3.329] [PMID:  10645931]

[8]
Gradman, A.H.; Basile, J.N.; Carter, B.L.; Bakris, G.L. Combination therapy in hypertension. J. Am. Soc. Hypertens.,  2010, 4(1), 42-50.
 [http://dx.doi.org/10.1016/j.jash.2010.02.005] [PMID:  20374950]

[9]
Takahara, A. Cilnidipine: A new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovasc. Ther.,  2009, 27(2), 124-139.
 [http://dx.doi.org/10.1111/j.1755-5922.2009.00079.x] [PMID:  19426250]

[10]
Uneyama, H.; Takahara, A.; Dohmoto, H.; Yoshimoto, R.; Inoue, K.; Akaike, N. Blockade of N-type Ca2+ current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurones. Br. J. Pharmacol.,  1997, 122(1), 37-42.
 [http://dx.doi.org/10.1038/sj.bjp.0701342] [PMID:  9298526]

[11]
Chandra, K.S.; Ramesh, G. The fourth-generation Calcium channel blocker. Cilnidipine. Indian Heart J.,  2013, 65(6), 691-695.
 [http://dx.doi.org/10.1016/j.ihj.2013.11.001] [PMID:  24407539]

[12]
Aounam, K.; Berdeaux, A. Therapie,  2003, 58(4), 333-339.
 [http://dx.doi.org/10.2515/therapie:2003051] [PMID:  14679672]

[13]
Uneyama, H.; Uchida, H.; Konda, T.; Yoshimoto, R. Cilnidipine: Preclinical profile and clinical evaluation. Cardiovasc. Drug Rev.,  1999, 17(4), 341-357.
 [http://dx.doi.org/10.1111/j.1527-3466.1999.tb00024.x]

[14]
Fujii, S.; Kameyama, K.; Hosono, M.; Hayashi, Y.; Kitamura, K. Effect of cilnidipine, a novel dihydropyridine Ca++-channel antagonist, on N-type Ca++ channel in rat dorsal root ganglion neurons. J. Pharmacol. Exp. Ther.,  1997, 280(3), 1184-1191.
 [PMID:  9067302]

[15]
Takahara, A.; Fujita, S.; Moki, K.; Ono, Y.; Koganei, H.; Iwayama, S.; Yamamoto, H. Neuronal Ca2+ channel blocking action of an antihypertensive drug, cilnidipine, in IMR-32 human neuroblastoma cells. Hypertens. Res.,  2003, 26(9), 743-747.
 [http://dx.doi.org/10.1291/hypres.26.743] [PMID:  14620931]

[16]
 The Japanese Pharmacopoeia. Available from: http://jpdb.nihs.go.jp/jp17e/000217650.pdf
          (Accessed January 23, 2020).

[17]

Indian Pharmacopoeia, 8th ed; The Indian Pharmacopoeia Commission: Ghaziabad, 2018. 

[18]
Cilnidipine. U.S. National Library of Medicine.  Available from: https://pubchem.ncbi.nlm.nih.gov/compound/5282138(Accessed	January 21, 2020).

[19]
Liu, X.Q.; Zhao, Y.; Li, D.; Qian, Z.Y.; Wang, G.J. Metabolism and metabolic inhibition of cilnidipine in human liver microsomes. Acta Pharmacol. Sin.,  2003, 24(3), 263-268.
 [PMID:  12617777]

[20]
Tominaga, M.; Ohya, Y.; Tsukashima, A.; Kobayashi, K.; Takata, Y.; Koga, T.; Yamashita, Y.; Fujishima, Y.; Abe, I.; Fujishima, M. Ambulatory blood pressure monitoring in patients with essential hypertension treated with a new calcium antagonist, cilnidipine. Cardiovasc. Drugs Ther.,  1997, 11(1), 43-48.
 [http://dx.doi.org/10.1023/A:1007795722576] [PMID:  9140677]

[21]
Fan, L.; Yang, Q.; Xiao, X.Q.; Grove, K.L.; Huang, Y.; Chen, Z.W.; Furnary, A.; He, G.W. Dual actions of cilnidipine in human internal thoracic artery: Inhibition of calcium channels and enhancement of endothelial nitric oxide synthase. J. Thorac. Cardiovasc. Surg.,  2011, 141(4), 1063-1069.
 [http://dx.doi.org/10.1016/j.jtcvs.2010.01.048] [PMID:  20599230]

[22]
Takami, T.; Shigemasa, M. Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients. Hypertens. Res.,  2003, 26(8), 609-614.
 [http://dx.doi.org/10.1291/hypres.26.609] [PMID:  14567499]

[23]
Hosono, M.; Fujii, S.; Hiruma, T.; Watanabe, K.; Hayashi, Y.; Ohnishi, H.; Takata, Y.; Kato, H. Inhibitory effect of cilnidipine on vascular sympathetic neurotransmission and subsequent vasoconstriction in spontaneously hypertensive rats. Jpn. J. Pharmacol.,  1995, 69(2), 127-134.
 [http://dx.doi.org/10.1254/jjp.69.127] [PMID:  8569049]

[24]
Nagai, H.; Minatoguchi, S.; Chen, X.H.; Wang, N.; Arai, M.; Uno, Y.; Lu, C.; Misao, Y.; Onogi, H.; Kobayashi, H.; Takemura, G.; Maruyama, R.; Fujiwara, T.; Fujiwara, H. Cilnidipine, an N+L-type dihydropyridine Ca channel blocker, suppresses the occurrence of ischemia/reperfusion arrhythmia in a rabbit model of myocardial infarction. Hypertens. Res.,  2005, 28(4), 361-368.
 [http://dx.doi.org/10.1291/hypres.28.361] [PMID:  16138567]

[25]
Onose, Y.; Oki, T.; Yamada, H.; Manabe, K.; Kageji, Y.; Matsuoka, M.; Yamamoto, T.; Tabata, T.; Wakatsuki, T.; Ito, S. Effect of cilnidipine on left ventricular diastolic function in hypertensive patients as assessed by pulsed Doppler echocardiography and pulsed tissue Doppler imaging. Jpn. Circ. J.,  2001, 65(4), 305-309.
 [http://dx.doi.org/10.1253/jcj.65.305] [PMID:  11316128]

[26]
Kitahara, Y.; Saito, F.; Akao, M.; Fujita, H.; Takahashi, A.; Taguchi, H.; Hino, T.; Otsuka, Y.; Kushiro, T.; Kanmatsuse, K. Effect of morning and bedtime dosing with cilnidipine on blood pressure, heart rate, and sympathetic nervous activity in essential hypertensive patients. J. Cardiovasc. Pharmacol.,  2004, 43(1), 68-73.
 [http://dx.doi.org/10.1097/00005344-200401000-00011] [PMID:  14668570]

[27]
Ashizawa, N.; Seto, S.; Shibata, Y.; Yano, K. Bedtime administration of cilnidipine controls morning hypertension. Int. Heart J.,  2007, 48(5), 597-603.
 [http://dx.doi.org/10.1536/ihj.48.597] [PMID:  17998769]

[28]
Nagahama, S.; Norimatsu, T.; Maki, T.; Yasuda, M.; Tanaka, S. The effect of combination therapy with an L/N-Type Ca(2+) channel blocker, cilnidipine, and an angiotensin II receptor blocker on the blood pressure and heart rate in Japanese hypertensive patients: An observational study conducted in Japan. Hypertens. Res.,  2007, 30(9), 815-822.
 [http://dx.doi.org/10.1291/hypres.30.815] [PMID:  18037774]

[29]
Sakata, K.; Shirotani, M.; Yoshida, H.; Nawada, R.; Obayashi, K.; Togi, K.; Miho, N. Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Hypertension,  1999, 33(6), 1447-1452.
 [http://dx.doi.org/10.1161/01.HYP.33.6.1447] [PMID:  10373231]

[30]
Minami, J.; Ishimitsu, T.; Kawano, Y.; Numabe, A.; Matsuoka, H. Comparison of 24-hour blood pressure, heart rate, and autonomic nerve activity in hypertensive patients treated with cilnidipine or nifedipine retard. J. Cardiovasc. Pharmacol.,  1998, 32(2), 331-336.
 [http://dx.doi.org/10.1097/00005344-199808000-00023] [PMID:  9700998]

[31]
Minami, J.; Kawano, Y.; Makino, Y.; Matsuoka, H.; Takishita, S. Effects of cilnidipine, a novel dihydropyridine calcium antagonist, on autonomic function, ambulatory blood pressure and heart rate in patients with essential hypertension. Br. J. Clin. Pharmacol.,  2000, 50(6), 615-620.
 [http://dx.doi.org/10.1046/j.1365-2125.2000.00299.x] [PMID:  11136301]

[32]
Pathapati, R.M.; Rajashekar, S.T.; Buchineni, M.; Meriga, R.K.; Reddy, C.B.; Kumar, K.P. An open label parallel group study to assess the effects of amlodipine and cilnidipine on pulse wave velocity and augmentation pressures in mild to moderate essential hypertensive patients. J. Clin. Diagn. Res.,  2015, 9(11), FC13-FC16.
 [http://dx.doi.org/10.7860/JCDR/2015/12702.6754] [PMID:  26676157]

[33]
Minami, J.; Ishimitsu, T.; Higashi, T.; Numabe, A.; Matsuoka, H. Comparison between cilnidipine and nisoldipine with respect to effects on blood pressure and heart rate in hypertensive patients. Hypertens. Res.,  1998, 21(3), 215-219.
 [http://dx.doi.org/10.1291/hypres.21.215] [PMID:  9786607]

[34]
Löhn, M.; Muzzulini, U.; Essin, K.; Tsang, S.Y.; Kirsch, T.; Litteral, J.; Waldron, P.; Conrad, H.; Klugbauer, N.; Hofmann, F.; Haller, H.; Luft, F.C.; Huang, Y.; Gollasch, M. Cilnidipine is a novel slow-acting blocker of vascular L-type calcium channels that does not target protein kinase C. J. Hypertens.,  2002, 20(5), 885-893.
 [http://dx.doi.org/10.1097/00004872-200205000-00023] [PMID:  12011649]

[35]
Sakaki, T.; Naruse, H.; Masai, M.; Takahashi, K.; Ohyanagi, M.; Iwasaki, T.; Fukuchi, M. Cilnidipine as an agent to lower blood pressure without sympathetic nervous activation as demonstrated by iodine-123 metaiodobenzylguanidine imaging in rat hearts. Ann. Nucl. Med.,  2003, 17(4), 321-326.
 [http://dx.doi.org/10.1007/BF02988529] [PMID:  12932117]

[36]
Takahara, A.; Nakamura, Y.; Wagatsuma, H.; Aritomi, S.; Nakayama, A.; Satoh, Y.; Akie, Y.; Sugiyama, A. Long-term blockade of L/N-type Ca2+ channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart. Br. J. Pharmacol.,  2009, 158(5), 1366-1374.
 [http://dx.doi.org/10.1111/j.1476-5381.2009.00407.x] [PMID:  19785655]

[37]
Leung, H.S.; Yao, X.; Leung, F.P.; Ko, W.H.; Chen, Z.Y.; Gollasch, M.; Huang, Y. Cilnidipine, a slow-acting Ca2+ channel blocker, induces relaxation in porcine coronary artery: Role of endothelial nitric oxide and.[Ca2+] Br. J. Pharmacol. ,  2006, 147(1), 55-63.
 [http://dx.doi.org/10.1038/sj.bjp.0706450] [PMID:  16299554]

[38]
Takai, S.; Jin, D.; Aritomi, S.; Niinuma, K.; Miyazaki, M. Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats. Hypertens. Res.,  2013, 36(4), 342-348.
 [http://dx.doi.org/10.1038/hr.2012.187] [PMID:  23190689]

[39]
Takeda, K.; Yamagishi, R.; Masumiya, H.; Tanaka, H.; Shigenobu, K. Effect of cilnidipine on L- and T-type calcium currents in guinea pig ventricle and action potential in rabbit sinoatrial node. J. Pharmacol. Sci.,  2004, 95(3), 398-401.
 [http://dx.doi.org/10.1254/jphs.SCJ04001X] [PMID:  15272218]

[40]
Shiga, T.; Yamada, Y.; Matsuda, N.; Tanaka, T.; Urae, A.; Hashiguchi, M.; Hagiwara, N.; Kasanuki, H. Influence of cilnidipine or nisoldipine on sympathetic activity in healthy male subjects. Heart Vessels,  2007, 22(6), 404-409.
 [http://dx.doi.org/10.1007/s00380-007-0984-y] [PMID:  18043999]

[41]
Kario, K.; Ando, S.; Kido, H.; Nariyama, J.; Takiuchi, S.; Yagi, T.; Shimizu, T.; Eguchi, K.; Ohno, M.; Kinoshita, O.; Yamada, T. The effects of the L/N-type calcium channel blocker (cilnidipine) on sympathetic hyperactive morning hypertension: Results from ACHIEVE-ONE. J. Clin. Hypertens. (Greenwich),  2013, 15(2), 133-142.
 [http://dx.doi.org/10.1111/jch.12042] [PMID:  23339732]

[42]
Hu, W.Y.; Fukuda, N.; Su, J.Z.; Kanmatsuse, K. Effects of the L- and N-type calcium channel blocker cilnidipine on growth of vascular smooth muscle cells from spontaneously hypertensive rats. J. Cardiovasc. Pharmacol.,  2001, 38(3), 450-459.
 [http://dx.doi.org/10.1097/00005344-200109000-00013] [PMID:  11486249]

[43]
Sugiyama, A.; Satoh, Y.; Takahara, A.; Ando, K.; Nakamura, Y.; Hashimoto, K. Comparison of the direct negative dromotropic effect of a new calcium channel blocker, cilnidipine, with that of nicardipine. Heart Vessels,  2005, 20(3), 112-115.
 [http://dx.doi.org/10.1007/s00380-004-0817-1] [PMID:  15912307]

[44]
Aritomi, S.; Harada, E.; Sugino, K.; Nishimura, M.; Nakamura, T.; Takahara, A. Comparison of the cardioprotective and renoprotective effects of the L/N‐type calcium channel blocker, cilnidipine, in adriamycin‐treated spontaneously‐hypertensive rats. Clin. Exp. Pharmacol. Physiol.,  2015, 42(4), 344-352.
 [http://dx.doi.org/10.1111/1440-1681.12360] [PMID:  25582553]

[45]
Hosono, M.; Hiruma, T.; Watanabe, K.; Hayashi, Y.; Ohnishi, H.; Takata, Y.; Kato, H. Inhibitory effect of cilnidipine on pressor response to acute cold stress in spontaneously hypertensive rats. Jpn. J. Pharmacol.,  1995, 69(2), 119-125.
 [http://dx.doi.org/10.1254/jjp.69.119] [PMID:  8569048]

[46]
Morimoto, S.; Takeda, K.; Oguni, A.; Kido, H.; Harada, S.; Moriguchi, J.; Itoh, H.; Nakata, T.; Sasaki, S.; Nakagawa, M. Reduction of white coat effect by cilnidipine in essential hypertension. Am. J. Hypertens.,  2001, 14(10), 1053-1057.
 [http://dx.doi.org/10.1016/S0895-7061(01)02159-8] [PMID:  11710785]

[47]
Matsuoka, S.; Kawamura, K.; Honda, M.; Awazu, M. White coat effect and white coat hypertension in pediatric patients. Pediatr. Nephrol.,  2002, 17(11), 950-953.
 [http://dx.doi.org/10.1007/s00467-002-0990-3] [PMID:  12432440]

[48]
Yamagishi, T. Beneficial effect of cilnidipine on morning hypertension and white-coat effect in patients with essential hypertension. Hypertens. Res.,  2006, 29(5), 339-344.
 [http://dx.doi.org/10.1291/hypres.29.339] [PMID:  16832154]

[49]
Kumar, N.; Singh, N.; Jaggi, A.S. Anti-stress effects of cilnidipine and nimodipine in immobilization subjected mice. Physiol. Behav.,  2012, 105(5), 1148-1155.
 [http://dx.doi.org/10.1016/j.physbeh.2011.12.011] [PMID:  22210395]

[50]
Tomiyama, H.; Kimura, Y.; Kuwabara, Y.; Maruyama, C.; Yoshida, Y.; Kuwata, S.; Kinouchi, T.; Yoshida, H.; Doba, N. Cilnidipine more highly attenuates cold pressor stress-induced platelet activation in hypertension than does amlodipine. Hypertens. Res.,  2001, 24(6), 679-684.
 [http://dx.doi.org/10.1291/hypres.24.679] [PMID:  11768727]

[51]
Kojima, S.; Shida, M.; Yokoyama, H. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens. Res.,  2004, 27(6), 379-385.
 [http://dx.doi.org/10.1291/hypres.27.379] [PMID:  15253102]

[52]
Fujita, T.; Ando, K.; Nishimura, H.; Ideura, T.; Yasuda, G.; Isshiki, M.; Takahashi, K. Cilnidipine versus amlodipine randomised trial for evaluation in renal desease(CARTER) study investigators. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int.,  2007, 72(12), 1543-1549.
 [http://dx.doi.org/10.1038/sj.ki.5002623] [PMID:  17943080]

[53]
Morimoto, S.; Yano, Y.; Maki, K.; Iwasaka, T. Renal and vascular protective effects of cilnidipine in patients with essential hypertension. J. Hypertens.,  2007, 25(10), 2178-2183.
 [http://dx.doi.org/10.1097/HJH.0b013e3282c2fa62] [PMID:  17885563]

[54]
Akira, T.; Hideki, D.; Hiroaki, H.; Susumu, S.; Ryota, Y. Cilnidipine attenuates renal nerve stimulation-induced renal vasoconstriction and antinatriuresis in anesthetized dogs. Jpn. J. Pharmacol.,  1997, 75(1), 27-32.
 [http://dx.doi.org/10.1016/S0021-5198(19)31344-7] [PMID:  9334883]

[55]
Rose, G.W.; Kanno, Y.; Ikebukuro, H.; Kaneko, M.; Kaneko, K.; Kanno, T.; Ishida, Y.; Suzuki, H. Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis. Hypertens. Res.,  2001, 24(4), 377-383.
 [http://dx.doi.org/10.1291/hypres.24.377] [PMID:  11510750]

[56]
Fan, Y.Y.; Kohno, M.; Nakano, D.; Ohsaki, H.; Kobori, H.; Suwarni, D.; Ohashi, N.; Hitomi, H.; Asanuma, K.; Noma, T.; Tomino, Y.; Fujita, T.; Nishiyama, A. Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: Possible involvement of N-type calcium channel in podocyte. J. Hypertens.,  2010, 28(5), 1034-1043.
 [http://dx.doi.org/10.1097/HJH.0b013e328336ade3] [PMID:  20411599]

[57]
Konno, Y.; Kimura, K. Vasodilatory effect of cilnidipine, an L-type and N-type calcium channel blocker, on rat kidney glomerular arterioles. Int. Heart J.,  2008, 49(6), 723-732.
 [http://dx.doi.org/10.1536/ihj.49.723] [PMID:  19075488]

[58]
Konda, T.; Enomoto, A.; Takahara, A.; Yamamoto, H. Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats. Biol. Pharm. Bull.,  2006, 29(5), 933-937.
 [http://dx.doi.org/10.1248/bpb.29.933] [PMID:  16651722]

[59]
Hishikawa, K.; Takase, O.; Idei, M.; Fujito, T. Comparison of antioxidant activity of cilnidipine and amlodipine. Kidney Int.,  2009, 76(2), 230-231.
 [http://dx.doi.org/10.1038/ki.2009.146] [PMID:  19564858]

[60]
Soeki, T.; Kitani, M.; Kusunose, K.; Yagi, S.; Taketani, Y.; Koshiba, K.; Wakatsuki, T.; Orino, S.; Kawano, K.; Sata, M. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients. Hypertens. Res.,  2012, 35(11), 1058-1062.
 [http://dx.doi.org/10.1038/hr.2012.96] [PMID:  22763473]

[61]
Toba, H.; Yoshida, M.; Tojo, C.; Nakano, A.; Oshima, Y.; Kojima, Y.; Noda, K.; Wang, J.; Kobara, M.; Nakata, T. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin–angiotensin–aldosterone system in deoxycorticosterone acetate-salt hypertensive rats. Hypertens. Res.,  2011, 34(4), 521-529.
 [http://dx.doi.org/10.1038/hr.2010.279] [PMID:  21270815]

[62]
Uchida, S.; Takahashi, M.; Sugawara, M.; Saito, T.; Nakai, K.; Fujita, M.; Mochizuki, K.; Shin, I.; Morita, T.; Hikita, T.; Itakura, H.; Takahashi, Y.; Mizuno, S.; Ohno, Y.; Ito, K.; Ito, T.; Soma, M. Effects of the N/L-type calcium channel blocker cilnidipine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (J-CIRCLE study). J. Clin. Hypertens. (Greenwich),  2014, 16(10), 746-753.
 [http://dx.doi.org/10.1111/jch.12412] [PMID:  25264215]

[63]
Aritomi, S.; Koganei, H.; Wagatsuma, H.; Mitsui, A.; Ogawa, T.; Nitta, K.; Konda, T. The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet. Heart Vessels,  2010, 25(6), 549-555.
 [http://dx.doi.org/10.1007/s00380-010-0005-4] [PMID:  20922532]

[64]
Hatta, T.; Takeda, K.; Shiotsu, Y.; Sugishita, C.; Adachi, T.; Kimura, T.; Sonomura, K.; Kusaba, T.; Kishimioto, N.; Narumiya, H.; Tanda, S.; Tamagaki, K.; Yamada, K.; Kameyama, H.; Kido, H.; Harada, S.; Bito, Y.; Moriguchi, J.; Morimoto, S.; Okigaki, M.; Itoh, H.; Mori, Y.; Nakata, T.; Maki, K.; Sasaki, S.; Sawada, K.; Matsubara, H. Switching to an L/N-type calcium channel blocker shows renoprotective effects in patients with chronic kidney disease: The Kyoto Cilnidipine Study. J. Int. Med. Res.,  2012, 40(4), 1417-1428.
 [http://dx.doi.org/10.1177/147323001204000420] [PMID:  22971493]

[65]
Abe, M.; Maruyama, N.; Suzuki, H.; Inoshita, A.; Yoshida, Y.; Okada, K.; Soma, M. L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease. Heart Vessels,  2013, 28(4), 480-489.
 [http://dx.doi.org/10.1007/s00380-012-0274-1] [PMID:  22914905]

[66]
Lei, B.; Nakano, D.; Fujisawa, Y.; Liu, Y.; Hitomi, H.; Kobori, H.; Mori, H.; Masaki, T.; Asanuma, K.; Tomino, Y.; Nishiyama, A. N-type calcium channel inhibition with cilnidipine elicits glomerular podocyte protection independent of sympathetic nerve inhibition. J. Pharmacol. Sci.,  2012, 119(4), 359-367.
 [http://dx.doi.org/10.1254/jphs.12075FP] [PMID:  22863666]

[67]
Yano, K.; Takimoto, S.; Motegi, T.; Tomono, T.; Hagiwara, M.; Idota, Y.; Morimoto, K.; Takahara, A.; Ogihara, T. Role of P-glycoprotein in regulating cilnidipine distribution to intact and ischemic brain. Drug Metab. Pharmacokinet.,  2014, 29(3), 254-258.
 [http://dx.doi.org/10.2133/dmpk.DMPK-13-RG-072] [PMID:  24366438]

[68]
Takahara, A.; Konda, T.; Enomoto, A.; Kondo, N. Neuroprotective effects of a dual L/N-type Ca(2+) channel blocker cilnidipine in the rat focal brain ischemia model. Biol. Pharm. Bull.,  2004, 27(9), 1388-1391.
 [http://dx.doi.org/10.1248/bpb.27.1388] [PMID:  15340224]

[69]
Sakamoto, K.; Kawakami, T.; Shimada, M.; Yamaguchi, A.; Kuwagata, M.; Saito, M.; Nakahara, T.; Ishii, K. Histological protection by cilnidipine, a dual L/N-type Ca2+ channel blocker, against neurotoxicity induced by ischemia–reperfusion in rat retina. Exp. Eye Res.,  2009, 88(5), 974-982.
 [http://dx.doi.org/10.1016/j.exer.2008.12.011] [PMID:  19166832]

[70]
Lee, Y.J.; Park, K.H.; Park, H.H.; Kim, Y.J.; Lee, K.Y.; Kim, S.H.; Koh, S.H. Cilnidipine mediates a neuroprotective effect by scavenging free radicals and activating the phosphatidylinositol 3-kinase pathway. J. Neurochem.,  2009, 111(1), 90-100.
 [http://dx.doi.org/10.1111/j.1471-4159.2009.06297.x] [PMID:  19650875]

[71]
Son, J.W.; Choi, H.; Yoo, A.; Park, H.H.; Kim, Y.S.; Lee, K.Y.; Lee, Y.J.; Koh, S.H. Activation of the phosphatidylinositol 3-kinase pathway plays important roles in reduction of cerebral infarction by cilnidipine. J. Neurochem.,  2015, 135(1), 186-193.
 [http://dx.doi.org/10.1111/jnc.13254] [PMID:  26222278]

[72]
Murakami, M.; Nakagawasai, O.; Fujii, S.; Hosono, M.; Hozumi, S.; Esashi, A.; Taniguchi, R.; Okamura, T.; Suzuki, T.; Sasano, H.; Yanagisawa, T.; Tan-no, K.; Tadano, T.; Kitamura, K.; Kisara, K. Antinociceptive effect of cilnidipine, a novel N-type calcium channel antagonist. Brain Res.,  2000, 868(1), 123-127.
 [http://dx.doi.org/10.1016/S0006-8993(00)02295-2] [PMID:  10841896]

[73]
Koganei, H.; Shoji, M.; Iwata, S. Suppression of formalin-induced nociception by cilnidipine, a voltage-dependent calcium channel blocker. Biol. Pharm. Bull.,  2009, 32(10), 1695-1700.
 [http://dx.doi.org/10.1248/bpb.32.1695] [PMID:  19801830]

[74]
Harada, N.; Onaka, M.; Sakamoto, S.; Niwa, Y.; Nakaya, Y. Cilnidipine improves insulin sensitivity in the Otsuka Long-Evans Tokushima fatty rat, a model of spontaneous NIDDM. Cardiovasc. Drugs Ther.,  1999, 13(6), 519-523.
 [http://dx.doi.org/10.1023/A:1007827720807] [PMID:  10686661]

[75]
Yagi, S.; Goto, S.; Yamamoto, T.; Kurihara, S.; Katayama, S. Effect of cilnidipine on insulin sensitivity in patients with essential hypertension. Hypertens. Res.,  2003, 26(5), 383-387.
 [http://dx.doi.org/10.1291/hypres.26.383] [PMID:  12887129]

[76]
Ueshiba, H.; Miyachi, Y. Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. Intern. Med.,  2004, 43(7), 561-565.
 [http://dx.doi.org/10.2169/internalmedicine.43.561] [PMID:  15335180]

[77]
Fukumoto, S.; Ishimura, E.; Motoyama, K.; Morioka, T.; Kimoto, E.; Wakikawa, K.; Shoji, S.; Koyama, H.; Shoji, T.; Emoto, M.; Nishizawa, Y.; Inaba, M. Cilnidipine vs L-type calcium channel blockers evaluation of antihypertensive renoprotective effects in diabetic patients (CLEARED) study investigators. Antialbuminuric advantage of cilnidipine compared with L-type calcium channel blockers in type 2 diabetic patients with normoalbuminuria and microalbuminuria. Diabetes Res. Clin. Pract.,  2012, 97(1), 91-98.
 [http://dx.doi.org/10.1016/j.diabres.2012.01.024] [PMID:  22336632]

[78]
Aritomi, S.; Niinuma, K.; Ogawa, T.; Konda, T.; Nitta, K. Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats. Clin. Exp. Nephrol.,  2013, 17(1), 41-50.
 [http://dx.doi.org/10.1007/s10157-012-0677-4] [PMID:  23011292]

[79]
Takeda, S.; Ueshiba, H.; Hattori, Y.; Irie, M. Cilnidipine, the N- and L-type calcium channel antagonist, reduced on 24-h urinary catecholamines and C-peptide in hypertensive non-insulin-dependent diabetes mellitus. Diabetes Res. Clin. Pract.,  1999, 44(3), 197-205.
 [http://dx.doi.org/10.1016/S0168-8227(99)00053-4] [PMID:  10462143]

[80]
Abe, H.; Mita, T.; Yamamoto, R.; Komiya, K.; Kawaguchi, M.; Sakurai, Y.; Shimizu, T.; Ohmura, C.; Ikeda, F.; Kawamori, R.; Fujitani, Y.; Watada, H. Comparison of effects of cilnidipine and azelnidipine on blood pressure, heart rate and albuminuria in type 2 diabetics with hypertension: A pilot study. J. Diabetes Investig.,  2013, 4(2), 202-205.
 [http://dx.doi.org/10.1111/jdi.12003] [PMID:  24843653]

[81]
Katayama, K.; Nomura, S.; Ishikawa, H.; Murata, T.; Koyabu, S.; Nakano, T. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria. Kidney Int.,  2006, 70(1), 151-156.
 [http://dx.doi.org/10.1038/sj.ki.5000349] [PMID:  16710356]

[82]
Tanaka, M.; Sekioka, R.; Nishimura, T.; Ichihara, A.; Itoh, H. Effects of cilnidipine on sympathetic nerve activity and cardiorenal function in hypertensive patients with type 2 diabetes mellitus: Association with BNP and aldosterone levels. Diabetes Res. Clin. Pract.,  2014, 106(3), 504-510.
 [http://dx.doi.org/10.1016/j.diabres.2014.09.056] [PMID:  25458339]

[83]
Ahaneku, J.E.; Sakata, K.; Uranol, T.; Takada, Y.; Takada, A. Effects of cilnidipine on lipids, lipoproteins and fibrinolytic system in hypertensive patients. Drugs Exp. Clin. Res.,  2000, 26(4), 119-123.
 [PMID:  11109511]

[84]
Dangi, N.B.; Sudheer, A.; Rathod, S.P.; Sapkota, H.P. Effect of Amlodipine, Cilnidipine and Diltiazem on lipid profiles of hypertensive rats fed with high fat diet: A comparative study. Bull. Fac. Pharm. Cairo Univ.,  2016, 54(2), 137-143.
 [http://dx.doi.org/10.1016/j.bfopcu.2016.04.001]

[85]
Tan, H.; Li, L.; Zhang, W.; Ma, Z.; Zhong, X.; Li, J.; Wang, Y. Effects of cilnidipine on fibrinolysis in chinese hypertensive patients. Clin. Drug Investig.,  2005, 25(12), 777-783.
 [http://dx.doi.org/10.2165/00044011-200525120-00004] [PMID:  17532723]

[86]
Ahaneku, J.E.; Sakata, K.; Urano, T.; Takada, Y.; Takada, A. Influence of baseline values on lipids, lipoproteins and fibrinolytic parameters during treatment of hypertension with cilnidipine. Pharmacol. Res.,  2000, 41(1), 79-82.
 [http://dx.doi.org/10.1006/phrs.1999.0558] [PMID:  10600273]

[87]
Osterloh, I. The safety of amlodipine. Am. Heart J.,  1989, 118(5), 1114-1120.
 [http://dx.doi.org/10.1016/0002-8703(89)90838-7] [PMID:  2573265]

[88]
Shetty, R.; Vivek, G.; Tumkur, A.; Naha, K.; Raj, A.; Bairy, K.L. Excellent tolerance to cilnidipine in hypertensives with amlodipine - induced edema. N. Am. J. Med. Sci.,  2013, 5(1), 47-50.
 [http://dx.doi.org/10.4103/1947-2714.106203] [PMID:  23378956]

[89]
Adake, P.; Somashekar, H.S.; Mohammed Rafeeq, P.K.; Umar, D.; Basheer, B.; Baroudi, K. Comparison of amlodipine with cilnidipine on antihypertensive efficacy and incidence of pedal edema in mild to moderate hypertensive individuals: A prospective study. J. Adv. Pharm. Technol. Res.,  2015, 6(2), 81-85.
 [http://dx.doi.org/10.4103/2231-4040.154543] [PMID:  25878978]

[90]
Shimizu, H.; Nakagami, H.; Yasumasa, N.; Mariana, O.K.; Kyutoku, M.; Koriyama, H.; Nakagami, F.; Shimamura, M.; Rakugi, H.; Morishita, R. Cilnidipine, but not amlodipine, ameliorates osteoporosis in ovariectomized hypertensive rats through inhibition of the N-type calcium channel. Hypertens. Res.,  2012, 35(1), 77-81.
 [http://dx.doi.org/10.1038/hr.2011.143] [PMID:  21881574]

[91]
Oda, S.; Oda, T.; Takabuchi, S.; Nishi, K.; Wakamatsu, T.; Tanaka, T.; Adachi, T.; Fukuda, K.; Nohara, R.; Hirota, K. The calcium channel blocker cilnidipine selectively suppresses hypoxia-inducible factor 1 activity in vascular cells. Eur. J. Pharmacol.,  2009, 606(1-3), 130-136.
 [http://dx.doi.org/10.1016/j.ejphar.2009.01.012] [PMID:  19374868]

[92]
Lee, J.; Lee, H.; Jang, K.; Lim, K.S.; Shin, D.; Yu, K.S. Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers. Drug Des. Devel. Ther.,  2014, 8, 1781-1788.
 [http://dx.doi.org/10.2147/DDDT.S68574] [PMID:  25336921]

[93]
Mohanty, M.; Tripathy, K.P.; Srakar, S.; Srivastava, V. Evaluation of safety and tolerability of amlodipine and cilnidipine-A comparative study. Sch. J. App. Med. Sci,  2016, 4(8C), 2884-2894.

[94]
Sagarad, S.V. S, H.P. A prospective and open label study of use of cilnidipine and chlorthalidone fixed dose combination in Indian hypertensive patients, intolerant or uncontrolled on amlodipine and hydrochlorothiazide combination. Inter. J. Adv. Med.,  2017, 4(6), 1522-1527.
 [http://dx.doi.org/10.18203/2349-3933.ijam20174673]
Rights & Permissions Print Cite
Article Metrics
39
2
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1871525721666230224111518	Print ISSN 1871-5257
Publisher Name Bentham Science Publisher	Online ISSN 1875-6182
Cardiovascular & Hematological Agents in Medicinal Chemistry

A Comprehensive Insight on Pharmacological Properties of Cilnidipine: A Fourth-generation Calcium Channel Blocker

Abstract

Graphical Abstract

Medicinal Plants with Beneficial Properties on Diabetes and Hypertension

Cardiovascular & Hematological Agents in Medicinal Chemistry

A Comprehensive Insight on Pharmacological Properties of Cilnidipine: A Fourth-generation Calcium Channel Blocker

Abstract

Graphical Abstract

Call for Papers in Thematic Issues

Medicinal Plants with Beneficial Properties on Diabetes and Hypertension

Related Journals

Related Books

Related Articles
